Research
Hormonal
Semaglutide treatment is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) compared to placebo, though these are mostly mild to moderate.
Be prepared for gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but usually mild and temporary. Titration helps manage them.
StrongQualifiesHIGH confidence
However, the incidence of gastrointestinal side effects was significantly higher in patients treated with semaglutide.
Why this rating
Meta-analysis of 9 RCTs.
Source
Effects of once-weekly semaglutide in obese/overweight patients: A systematic review and meta-analysis
Mengjun Wang et al. · Research Square · 2022
DOI 10.21203/rs.3.rs-2346356/v1
Meta-analysis · 9 studies
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Once-weekly subcutaneous semaglutide (up to 2.4 mg) significantly reduces body weight, BMI, and waist circumference in adults with obesity or overweight compared to placebo, with effects demonstrating a dose-response relationship.Strong
- Once-weekly semaglutide improves cardiometabolic markers including HbA1c, fasting plasma glucose, blood pressure, and lipid profiles in overweight/obese patients, independent of or alongside weight loss.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →